Generic Seglentis Availability
Last updated on Jun 11, 2025.
Seglentis is a brand name of celecoxib/tramadol, approved by the FDA in the following formulation(s):
SEGLENTIS (celecoxib; tramadol hydrochloride - tablet;oral)
-
Manufacturer: KOWA PHARMS
Approval date: October 15, 2021
Strength(s): 56MG;44MG (discontinued) [RLD] [AB]
All of the above formulations have been discontinued.
Is there a generic version of Seglentis available?
No. There is currently no therapeutically equivalent version of Seglentis available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seglentis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Co-crystals of tramadol and coxibis
Patent 10,238,668
Issued: March 26, 2019
Inventor(s): Plata Salaman Carlos Ramon & Tesson Nicolas
Assignee(s): LABORATORIOS DEL DR. ESTEVE, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓✓✓
- April 19, 2030
-
Co-crystals of tramadol and coxibs
Patent 10,245,276
Issued: April 2, 2019
Inventor(s): Plata Salaman Carlos Ramon & Tesson Nicolas
Assignee(s): LABORATORIOS DEL DR. ESTEVE, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓✓
- April 19, 2030
-
Co-crystals of tramadol and coxibs
Patent 10,548,909
Issued: February 4, 2020
Inventor(s): Plata Salaman Carlos Ramon & Tesson Nicolas
Assignee(s): ESTEVE PHARMACEUTICALS, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓
- April 19, 2030
-
Co-crystals of tramadol and coxibs
Patent 11,478,488
Issued: October 25, 2022
Inventor(s): Plata-Salaman Carlos-Ramón & Tesson Nicolas
Assignee(s): ESTEVE PHARMACEUTICALS, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓
- April 19, 2030
-
Co-crystals of tramadol and coxibs
Patent 8,598,152
Issued: December 3, 2013
Inventor(s): Plata Salaman Carlos Ramon & Tesson Nicolas
Assignee(s): Laboratorios Del Dr. Esteve, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓✓
- April 19, 2030
-
Pharmaceutical compositions of co-crystals of tramadol and coxibs
Patent 8,846,744
Issued: September 30, 2014
Inventor(s): Soler Ranzani Luis & Falivene Aldea Albert
Assignee(s): Laboratorios del Dr. Esteve, S.A.The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib and processes for the preparation of these oral pharmaceutical compositions. The present invention also relates to methods of using oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib as medicaments, more particularly for the treatment of pain.
Patent expiration dates:
- June 3, 2031✓
- June 3, 2031
-
Co-crystals of tramadol and coxibs
Patent 9,012,440
Issued: April 21, 2015
Inventor(s): Plata Salaman Carlos Ramon & Tesson Nicolas
Assignee(s): Laboratorios del Dr. Esteve, S.A.The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain.
Patent expiration dates:
- April 19, 2030✓✓
- April 19, 2030
More about Seglentis (celecoxib / tramadol)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: narcotic analgesic combinations
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Paracetamol
Paracetamol (Panadol, Calpol, Alvedon) is a widely used over-the-counter painkiller and fever ...
Tylenol
Tylenol is a pain reliever and a fever reducer used to treat many conditions such as headaches ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Oxycodone
Oxycodone is an opioid analgesic used to treat moderate to severe pain; it has a high potential for ...
Naproxen
Naproxen is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Hydroxyzine
Hydroxyzine is an antihistamine used to treat itching, hives, and anxiety. It also acts as a ...
Tramadol
Tramadol is an opioid medication that may be used to treat moderate to moderately severe chronic ...
Cyclobenzaprine
Cyclobenzaprine is a muscle relaxant and works by blocking pain sensations. Includes ...
Meloxicam
Meloxicam is a nonsteroidal anti-inflammatory drug used to treat pain or inflammation caused by ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
